Physician profile
David J Smith
NPI 1275623662
$5,760.10
in general payments reported to CMS, 2019-2025
33 companies · $33.31 in 2025
The $33.31 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $453 · 2021: $677 · 2022: $2,306 · 2023: $915 · 2024: $52.10 · 2025: $33.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,557.68 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,167.55 | 2021-2023 | |
| Abbvie INC. | $623.58 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $332.48 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $315.02 | 2019-2023 | Jardiance, Amyvid, Mounjaro |
| Amgen INC. | $268.90 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $267.22 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.26 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $113.33 | 2019-2022 | |
| Glaxosmithkline, LLC. | $99.07 | 2020-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Boston Scientific Corporation | $91.29 | 2020 | |
| Merck Sharp & Dohme LLC | $81.63 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Amarin Pharma, INC. | $76.38 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $76.20 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $65.66 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $56.70 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.63 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $49.89 | 2021 | |
| Sanofi Pasteur INC. | $39.42 | 2021-2022 | |
| Dexcom, INC. | $38.90 | 2022-2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $35.32 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.65 | 2023 | |
| Grt US Holding, INC. | $29.15 | 2022 | |
| Abbott Laboratories | $18.55 | 2025 | Freestyle Libre 3 |
| Grifols USA, LLC | $18.51 | 2024 | Prolastin-C Liquid |
| Halozyme INC | $18.01 | 2023 | |
| Radius Health, INC. | $17.35 | 2023 | Tymlos |
| Mylan Specialty L.P. | $16.52 | 2019 | |
| Averitas Pharma INC. | $14.41 | 2023 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $13.52 | 2019 | |
| Gilead Sciences, INC. | $13.20 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.